An interventional study of Orbital atherectomy and Intravascular lithotripsy in Coronary Arterial Disease (CAD), Coronary Calcification and Coronary Calcified Nodules, sponsored by Spanish Society of Cardiology. Recruiting at 6 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-30.
Sponsored by Spanish Society of Cardiology · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.
Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 56th largest by planned enrollment of the 60 interventional ones that give a count, is one of 6 that started in 2025, is one of 24 with no phase, reaches primary completion later than 6 of the 15 other live ones, and was the 74th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Kristian Rivera · Sites in Spain, Mexico
Ages 18+
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, Ireland, Latvia and 2 more countries
Ages 18+
Ceric Sàrl · Sites in Spain
Ages 18+
Fundación para la Investigación del Hospital Clínico de Valencia · Sites in Spain
Ages 65+
Abcentra · Sites in Spain, United States, Czechia and 6 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 588 across the 60 interventional studies, 900 across the 25 observational. Of the 58 that completed or were terminated, 20 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 85 have an industry lead sponsor. The 10 most frequent:
Spanish Society of Cardiology is the lead sponsor of 23 studies on the registry; 6 are open to participants now.
Spanish Society of Cardiology has 2 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute Coronary Syndrome with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT06736665Spanish Society of CardiologyOrbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK). | 2026-12 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
| NCT07038265Institut d'Investigació Biomèdica de BellvitgePatient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Acute Coronary Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI).
Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).
The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting calcified nodules (CN), identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI). Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).
The aim of this pilot trial is to compare PCI outcomes and the incidence of adverse events between both techniques.
Coronary calcification in the form of calcified nodules (CN) is systematically associated with worse outcomes due to the difficulty in adequately dilation of the lesion and the inability to properly fracture the calcium nodule before stent implantation.
The ORBIT-SHOCK pilot study is a multicenter, prospective, randomized clinical trial initiated by investigators. It will include patients diagnosed with atherosclerotic coronary artery disease presenting CNs, identified by optical coherence tomography (OCT), causing significant angiographic stenosis and eligible for revascularization through percutaneous coronary intervention (PCI).
Patients will be randomized in a 1:1 ratio to undergo lesion preparation with either orbital atherectomy (OA) or intravascular lithotripsy (IVL).
Primary endpoint: Compare both techniques in terms of achieving adequate stent expansion, measured by OCT.
Secondary endpoints: Evaluate procedural and strategy success rates, assess their impact on calcium nodule modification, and monitor the incidence of adverse clinical events at 12 months.
Patients will be monitored for 12 months after the procedure to assess the incidence of adverse events during follow-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.
Device: Orbital atherectomy · Device: Optical Coherence Tomography (OCT) · Device: Percutaneous coronary intervention with stent implantation
The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.
Device: Intravascular lithotripsy · Device: Optical Coherence Tomography (OCT) · Device: Percutaneous coronary intervention with stent implantation
The Diamondback-360 (OAS) (Abbott) device is used to perform this technique, consisting of a bidirectional, diamond-coated orbital crown that utilizes a combination of centrifugal force (creating elliptical orbits) and surface abrasion to modify the calcified plaque and increase distensibility. Additionally, the pulsatile impact of the crown at high speed can create microfractures in deep calcium. As a result, a single 1.25 mm crown can treat vessels ranging from 2.5 to 4 mm in diameter.
The Shockwave Medical Intravascular Lithotripsy System (Shockwave Medical) is a balloon that emits pulsatile sonic waves capable of fracturing intracoronary calcium. This therapy is administered by advancing a catheter and inflating the balloon at low pressure to deliver sonic pulses.
Also known as: Shockwave
Optical Coherence Tomography (OCT) is an intravascular imaging modality that uses near-infrared light to provide high-definition, cross-sectional and three-dimensional images of the vessel microstructure. These images provide additional information on the degree and characteristics of coronary artery disease compared to angiography which doesn't delineate the composition of the coronary artery. With automated, highly accurate measurements, OCT can guide stent selection, placement, and deployment.
All patients will undergo percutaneous coronary intervention with drug-eluting stent implantation after plaque modification using the technique assigned by randomization.
Stent expansion
Percentage of stent expansion at the CN site: measured with OCT, defined as the ratio between the minimum stent area at the CN site and the average of the distal and proximal reference areas.
Time frame: At the end of percutaneous coronary intervention
Procedural success
Achieving a stent expansion of ≥ 80% with TIMI III flow, in the absence of stent loss, coronary perforation, or intraprocedural death.
Time frame: At the end of percutaneous coronary intervention
Strategy success
Defined as procedural success without the need for crossover to an alternative treatment.
Time frame: At the end of percutaneous coronary intervention
Minimum stent area
Minimum stent area (MSA)
Time frame: At the end of percutaneous coronary intervention
Minimum stent area at the CN site.
Minimum stent area at the CN site.
Time frame: At the end of percutaneous coronary intervention
Significant stent malapposition at the CN site
Measured using OCT, defined as a stent strut detachment ≥ 0.4 mm from the underlying vessel wall, with a longitudinal extension ≥ 1 mm.
Time frame: At the end of percutaneous coronary intervention
Degree of calcium nodule debulking
Reduction in calcium nodule size (mm²), measured after plaque modification and prior to stent implantation.
Time frame: At the end of percutaneous coronary intervention
Evidence of fracture at the CN site
Evidence of new disruption or discontinuity observed on OCT after plaque modification and prior to stent implantation.
Time frame: At the end of percutaneous coronary intervention
Degree of stent ellipticity at the CN site
Measured using OCT at the end of the procedure, calculated as the ratio of the maximum luminal diameter to the minimum luminal diameter of the stent at the CN site.
Time frame: At the end of percutaneous coronary intervention
Residual luminal protrusion of the calcium nodule following stent implantation
Residual luminal protrusion of the calcium nodule following stent implantation, measured by OCT in mm2.
Time frame: At the end of percutaneous coronary intervention
Target lesion failure (TLF) at 12 months
Composite of clinically driven target lesion revascularization, myocardial infarction or cardiac death related to the target lesion.
Time frame: At 12 months
Target lesion revascularization (TLR) at 12 months
Repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.
Time frame: At 12 months
Major Adverse Cardiovascular Events (MACE) at 12 months
Defined as a composite of cardiovascular death, non-fatal target lesion myocardial infarction, unplanned target lesion revascularization or stent thrombosis.
Time frame: At 12 months
Plan to share: Undecided
Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.
Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 18 months is below that.
Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spanish Society of Cardiology